Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy).

Garcia J, Forestier J, Dusserre E, Wozny AS, Geiguer F, Merle P, Tissot C, Ferraro-Peyret C, Jones FS, Edelstein DL, Cheynet V, Bardel C, Vilchez G, Xu Z, Bringuier PP, Barritault M, Brengle-Pesce K, Guillet M, Chauvenet M, Manship B, Brevet M, Rodriguez-Lafrasse C, Hervieu V, Couraud S, Walter T, Payen L.

Oncotarget. 2018 Apr 20;9(30):21122-21131. doi: 10.18632/oncotarget.24950. eCollection 2018 Apr 20.

2.

[Multiple lung carcinoma: Primary or intrapulmonary metastasis?]

Ravella L, Barritault M, Bringuier PP, Chalabreysse L, Thivolet-Bejui F, Maury JM, Duruisseaux M, Brevet M.

Ann Pathol. 2018 Jun;38(3):202-205. doi: 10.1016/j.annpat.2018.02.001. Epub 2018 Mar 17. French.

PMID:
29555057
3.

Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study.

Garcia J, Dusserre E, Cheynet V, Bringuier PP, Brengle-Pesce K, Wozny AS, Rodriguez-Lafrasse C, Freyer G, Brevet M, Payen L, Couraud S.

Oncotarget. 2017 Sep 21;8(50):87980-87996. doi: 10.18632/oncotarget.21256. eCollection 2017 Oct 20.

4.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT).

Ann Oncol. 2017 Nov 1;28(11):2715-2724. doi: 10.1093/annonc/mdx404.

PMID:
28945865
5.

Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.

Boespflug A, Funck-Brentano E, Hélias-Rodzewicz Z, Maucort-Boulch D, Beauchet A, Bringuier PP, Dumontet C, Emile JF, Saiag P, Dalle S.

Pigment Cell Melanoma Res. 2017 Sep;30(5):498-500. doi: 10.1111/pcmr.12606. Epub 2017 Jul 23. No abstract available.

PMID:
28627072
6.

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G; Biomarkers France contributors.

Lancet. 2016 Apr 2;387(10026):1415-1426. doi: 10.1016/S0140-6736(16)00004-0. Epub 2016 Jan 15.

7.

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.

Tissot C, Couraud S, Tanguy R, Bringuier PP, Girard N, Souquet PJ.

Lung Cancer. 2016 Jan;91:23-8. doi: 10.1016/j.lungcan.2015.11.006. Epub 2015 Nov 15.

PMID:
26711930
8.

Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.

de la Fouchardiere C, Oussaid N, Derbel O, Decaussin-Petrucci M, Fondrevelle ME, Wang Q, Bringuier PP, Bournaud-Salinas C, Peix JL, Lifante JC, Giraudet AL, Lopez J, Borson-Chazot F.

Target Oncol. 2016 Feb;11(1):71-82. doi: 10.1007/s11523-015-0380-y.

PMID:
26285789
9.

KIT Mutation and Loss of 14q May Be Sufficient for the Development of Clinically Symptomatic Very Low-Risk GIST.

Klinke OK, Mizani T, Baldwin G, Bancel B, Devouassoux-Shisheboran M, Scoazec JY, Bringuier PP, Feederle R, Jauch A, Hinderhofer K, Taniere P, Delecluse HJ.

PLoS One. 2015 Jun 23;10(6):e0130149. doi: 10.1371/journal.pone.0130149. eCollection 2015.

10.

Involvement of orphan nuclear receptor COUP-TFII in cadherin-6 and cadherin-11 regulation: implications in development and cancer.

Bringuier PP, Schalken JA, Hervieu V, Giroldi LA.

Mech Dev. 2015 May;136:64-72. doi: 10.1016/j.mod.2015.02.001. Epub 2015 Feb 14.

11.

KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.

Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, Sufliarsky J, Federico M, Jonasson JG, Hostein I, Bringuier PP, Emile JF.

J Clin Oncol. 2015 Feb 20;33(6):634-42. doi: 10.1200/JCO.2014.57.4970. Epub 2015 Jan 20.

PMID:
25605837
12.

Comment on: 'COUP-TFII regulates metastasis of colorectal adenocarcinoma cells by modulating Snail1'.

Bringuier PP, Giroldi LA.

Br J Cancer. 2015 May 26;112(11):1836. doi: 10.1038/bjc.2014.613. Epub 2014 Dec 9. No abstract available.

13.

Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC).

Confavreux CB, Girard N, Pialat JB, Bringuier PP, Devouassoux-Shisheboran M, Rousseau JC, Isaac S, Thivolet-Bejui F, Clezardin P, Brevet M.

Bonekey Rep. 2014 Oct 1;3:580. doi: 10.1038/bonekey.2014.75. eCollection 2014.

14.

Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy.

Perier-Muzet M, Thomas L, Poulalhon N, Debarbieux S, Bringuier PP, Duru G, Depaepe L, Balme B, Dalle S.

J Invest Dermatol. 2014 May;134(5):1351-1358. doi: 10.1038/jid.2013.462. Epub 2013 Nov 7.

15.

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.

Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de Fraipont F, Bièche I, de Cremoux P, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalcman G, Cadranel J.

J Mol Diagn. 2014 Jan;16(1):45-55. doi: 10.1016/j.jmoldx.2013.07.009. Epub 2013 Oct 30.

PMID:
24183959
16.

Microarray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages.

Descotes F, Dessen P, Bringuier PP, Decaussin M, Martin PM, Adams M, Villers A, Lechevallier E, Rebillard X, Rodriguez-Lafrasse C, Devonec M, Paparel P, Perrin P, Lazar V, Ruffion A.

BJU Int. 2014 Feb;113(2):333-42. doi: 10.1111/bju.12364. Epub 2013 Oct 31.

17.

Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.

Locatelli-Sanchez M, Couraud S, Arpin D, Riou R, Bringuier PP, Souquet PJ.

Lung. 2013 Oct;191(5):491-9. doi: 10.1007/s00408-013-9482-4. Epub 2013 Jun 9.

PMID:
23749122
18.

Tracking of second primary melanomas in vemurafenib-treated patients.

Dalle S, Poulalhon N, Debarbieux S, Zaharia D, Mihm MC, Lacouture ME, Rosen A, Marghoob AA, Busam KJ, Depaepe L, Bringuier PP, Richez P, Baurain JF, Bressac-de Paillerets B, Balme B, Thomas L.

JAMA Dermatol. 2013 Apr;149(4):488-90. doi: 10.1001/jamadermatol.2013.21. No abstract available.

PMID:
23715012
19.

Primary lung adenocarcinoma occurring in a PTEN related syndrome (Cowden's disease): routine EGFR sequencing also highlights two rare somatic mutations S768I and V769L.

Boespflug A, Couraud S, Bringuier PP, Isaac S, Gérinière L, Perrot E, Edery P, Durieu I, Souquet PJ.

Lung Cancer. 2013 Mar;79(3):318-20. doi: 10.1016/j.lungcan.2012.11.020. Epub 2012 Dec 20.

PMID:
23261230
20.

Molecular characterisation of gastrointestinal stromal tumours in a South African population.

Baker G, Babb C, Schnugh D, Nayler S, Louw M, Goedhals J, Bringuier PP, Blay JY, Willem P.

Oncol Lett. 2013 Jan;5(1):155-160. Epub 2012 Nov 5.

21.

Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs.

Emile JF, Brahimi S, Coindre JM, Bringuier PP, Monges G, Samb P, Doucet L, Hostein I, Landi B, Buisine MP, Neuville A, Bouché O, Cervera P, Pretet JL, Tisserand J, Gauthier A, Le Cesne A, Sabourin JC, Scoazec JY, Bonvalot S, Corless CL, Heinrich MC, Blay JY, Aegerter P.

Med Oncol. 2012 Sep;29(3):1765-72. doi: 10.1007/s12032-011-0074-y. Epub 2011 Sep 28.

PMID:
21953054
22.

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing.

Ducimetière F, Lurkin A, Ranchère-Vince D, Decouvelaere AV, Péoc'h M, Istier L, Chalabreysse P, Muller C, Alberti L, Bringuier PP, Scoazec JY, Schott AM, Bergeron C, Cellier D, Blay JY, Ray-Coquard I.

PLoS One. 2011;6(8):e20294. doi: 10.1371/journal.pone.0020294. Epub 2011 Aug 3.

23.

A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours.

Hostein I, Debiec-Rychter M, Olschwang S, Bringuier PP, Toffolati L, Gonzalez D, Forget S, Escande F, Morzuch L, Tamborini E, Faur N, Pilotti S, Dei Tos P, Emile JF, Coindre JM.

J Gastroenterol. 2011 May;46(5):586-94. doi: 10.1007/s00535-011-0375-0. Epub 2011 Feb 1.

PMID:
21286759
24.

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.

Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, Ray-Coquard I, Cupissol D, Chevreau C, Perol D, Goncalves A, Jimenez M, Bringuier PP, Blay JY.

Br J Cancer. 2010 Aug 10;103(4):482-5. doi: 10.1038/sj.bjc.6605783. Epub 2010 Jul 27.

25.

A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region.

Cassier PA, Ducimetière F, Lurkin A, Ranchère-Vince D, Scoazec JY, Bringuier PP, Decouvelaere AV, Méeus P, Cellier D, Blay JY, Ray-Coquard I.

Br J Cancer. 2010 Jul 13;103(2):165-70. doi: 10.1038/sj.bjc.6605743. Epub 2010 Jun 29.

26.

[Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhône-Alpes region].

Ducimetière F, Lurkin A, Ranchère-Vince D, Decouvelaere AV, Isaac S, Claret-Tournier C, Suignard Y, Salameire D, Cellier D, Alberti L, Bringuier PP, Blay JY, Ray-Coquard I.

Bull Cancer. 2010 Jun;97(6):629-41. doi: 10.1684/bdc.2010.1117. Review. French.

27.

BRAF mutation status in gastrointestinal stromal tumors.

Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, Bringuier PP, Scoazec JY, Coindre JM.

Am J Clin Pathol. 2010 Jan;133(1):141-8. doi: 10.1309/AJCPPCKGA2QGBJ1R.

PMID:
20023270
28.

Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib.

Cassier PA, Dufresne A, Arifi S, El Sayadi H, Ray-Coquard I, Bringuier PP, Scoazec JY, Alberti L, Blay JY.

Curr Gastroenterol Rep. 2008 Dec;10(6):555-61. Review.

PMID:
19006610
29.

Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion.

Amiot A, Dokmak S, Sauvanet A, Vilgrain V, Bringuier PP, Scoazec JY, Sastre X, Ruszniewski P, Bedossa P, Couvelard A.

JOP. 2008 May 8;9(3):339-45.

30.

2-Arylidenedihydroindole-3-ones: design, synthesis, and biological activity on bladder carcinoma cell lines.

Gerby B, Boumendjel A, Blanc M, Bringuier PP, Champelovier P, Fortuné A, Ronot X, Boutonnat J.

Bioorg Med Chem Lett. 2007 Jan 1;17(1):208-13. Epub 2006 Oct 16.

PMID:
17049235
31.

Expression of beta-catenin in gastroenteropancreatic endocrine tumours: a study of 229 cases.

Hervieu V, Lepinasse F, Gouysse G, Guillaud O, Barel C, Chambonniere ML, Bringuier PP, Poncet G, Lombard-Bohas C, Partensky C, Chayvialle JA, Scoazec JY.

J Clin Pathol. 2006 Dec;59(12):1300-4. Epub 2006 May 26.

32.

[Multiple gastro-intestinal stromal tumors (GIST) in a patient with type I neurofibromatosis revealed by chronic bleeding: pre-operative radiological diagnosis].

Guillaud O, Dumortier J, Bringuier PP, Saurin JC, Poncet G, Boulez J, Henry L, Chayvialle JA, Scoazec JY.

Gastroenterol Clin Biol. 2006 Feb;30(2):320-4. French.

33.

Imatinib in patients with metastatic gastrointestinal stromal tumours relapsing after hepatic transplantation.

Bompas E, Boillot O, Bringuier PP, Dumortier J, Blay JY.

Eur J Cancer. 2004 Jun;40(9):1456-7. No abstract available.

PMID:
15177508
34.

Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation.

Fiorentino M, Altimari A, Ravaioli M, Gruppioni E, Gabusi E, Corti B, Vivarelli M, Bringuier PP, Scoazec JY, Grigioni WF, D'Errico-Grigioni A.

Clin Cancer Res. 2004 Mar 1;10(5):1789-95.

35.

Classical cadherins in urological cancers.

Giroldi LA, Shimazui T, Schalken JA, Yamasaki H, Bringuier PP.

Morphologie. 2000 Jun;84(265):31-8. Review.

PMID:
11048296
36.

Alterations in expression of cadherin-6 and E-cadherin during kidney development and in renal cell carcinoma.

Shimazui T, Oosterwijk-Wakka J, Akaza H, Bringuier PP, Ruijter E, Debruyne FM, Schalken JA, Oosterwijk E.

Eur Urol. 2000 Sep;38(3):331-8.

PMID:
10940709
37.

Mechanisms associated with abnormal E-cadherin immunoreactivity in human bladder tumors.

Bringuier PP, Giroldi LA, Umbas R, Shimazui T, Schalken JA.

Int J Cancer. 1999 Nov 26;83(5):591-5.

38.

Changes in cadherin-catenin complexes in the progression of human bladder carcinoma.

Giroldi LA, Bringuier PP, Shimazui T, Jansen K, Schalken JA.

Int J Cancer. 1999 Jul 2;82(1):70-6.

39.

Astrocytomas and choroid plexus tumors in two families with identical p53 germline mutations.

Vital A, Bringuier PP, Huang H, San Galli F, Rivel J, Ansoborlo S, Cazauran JM, Taillandier L, Kleihues P, Ohgaki H.

J Neuropathol Exp Neurol. 1998 Nov;57(11):1061-9.

PMID:
9825943
40.

Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogen-metabolising enzymes.

Bringuier PP, McCredie M, Sauter G, Bilous M, Stewart J, Mihatsch MJ, Kleihues P, Ohgaki H.

Int J Cancer. 1998 Oct 23;79(5):531-6.

41.

Role of E boxes in the repression of E-cadherin expression.

Giroldi LA, Bringuier PP, de Weijert M, Jansen C, van Bokhoven A, Schalken JA.

Biochem Biophys Res Commun. 1997 Dec 18;241(2):453-8.

PMID:
9425291
42.

Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma.

Shimazui T, Bringuier PP, van Berkel H, Ruijter E, Akaza H, Debruyne FM, Oosterwijk E, Schalken JA.

Int J Cancer. 1997 Oct 21;74(5):523-8.

43.

Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer.

Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM, Schalken JA.

Int J Cancer. 1997 Aug 22;74(4):374-7.

44.

Homozygous deletions of p16(INK4) occur frequently in bilharziasis-associated bladder cancer.

Tamimi Y, Bringuier PP, Smit F, van Bokhoven A, Abbas A, Debruyne FM, Schalken JA.

Int J Cancer. 1996 Oct 9;68(2):183-7.

45.

Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors.

Shimazui T, Schalken JA, Giroldi LA, Jansen CF, Akaza H, Koiso K, Debruyne FM, Bringuier PP.

Cancer Res. 1996 Sep 15;56(18):4154-8.

46.

Complex cadherin expression in renal cell carcinoma.

Shimazui T, Giroldi LA, Bringuier PP, Oosterwijk E, Schalken JA.

Cancer Res. 1996 Jul 15;56(14):3234-7.

47.

p16 mutations/deletions are not frequent events in prostate cancer.

Tamimi Y, Bringuier PP, Smit F, van Bokhoven A, Debruyne FM, Schalken JA.

Br J Cancer. 1996 Jul;74(1):120-2.

48.

Loss of chromosome 9 in tissue sections of transitional cell carcinomas as detected by interphase cytogenetics. A comparison with RFLP analysis.

Poddighe PJ, Bringuier PP, Vallinga M, Schalken JA, Ramaekers FC, Hopman AH.

J Pathol. 1996 Jun;179(2):169-76.

PMID:
8758209
49.

Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification.

Bringuier PP, Tamimi Y, Schuuring E, Schalken J.

Oncogene. 1996 Apr 18;12(8):1747-53.

PMID:
8622895
50.

Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.

Vet JA, Bringuier PP, Schaafsma HE, Witjes JA, Debruyne FM, Schalken JA.

Lab Invest. 1995 Dec;73(6):837-43.

PMID:
8558845

Supplemental Content

Loading ...
Support Center